In conclusion, the rationale to utilize the optimal treatment schedule of the FUL-OXA combination capable of inducing both growth inhibition and CEA up-regulation, appears to be of considerable value, since drug-induced overexpression of the antigen is expected to make tumor cells more susceptible to the cytolytic activity of specific effector lymphocytes. The gene discussed is CEACAM5; the disease is neoplasm.